



吉林省輝南長龍生化藥業股份有限公司
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8049)

Third Quarterly Report 2008

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET (“GEM”) OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate companies to which a high investment risk may be attached then other companies listed on the Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

The principal means of information dissemination on GEM is publication on the internet website operated by the Stock Exchange. Listed companies are not generally required to issue paid announcements in gazette newspapers. Accordingly, prospective investors should note that they need to have access to the GEM website (www.hkgem.com) in order to obtain up-to-date information on GEM-listed issuers.

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this report, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors of the Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “Directors”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the “GEM Listing Rules”) for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited and its subsidiaries (“the Group”). The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

THIRD QUARTERLY REPORT (UNAUDITED)

For the nine months ended 30 September 2008

CONSOLIDATED PROFIT AND LOSS ACCOUNT (UNAUDITED)

The Board of Directors (the "Board") of Jilin Province Huinan Changlong Biopharmacy Company Limited ("the Company") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the "Group") for the nine months and three months ended 30 September, 2008 together with the comparative unaudited figures for the corresponding periods in 2007 as follows:

		For the nine months ended 30 September		For the three months ended 30 September	
		2008	2007	2008	2007
	Notes	RMB'000	RMB'000	RMB'000	RMB'000
Turnover	3	83,845	65,204	33,410	25,784
Cost of sales		(17,683)	(17,504)	(7,890)	(7,518)
Gross profit		66,162	47,700	25,520	18,266
Other revenue		349	169	46	54
Distribution and selling costs		(39,126)	(28,842)	(15,190)	(11,759)
Administrative expenses		(12,256)	(11,422)	(3,380)	(3,307)
Profit from operations		15,129	7,605	6,996	3,254
Finance costs		(72)	(27)	(24)	(23)
Profit before taxation		15,057	7,578	6,972	3,231
Taxation	5	(3,830)	(2,555)	(1,784)	(1,087)
Profit attributable to equity holders of the Company		11,227	5,023	5,188	2,144
Earnings per share – Basic	6	2.00 cents	0.90 cents	0.92 cents	0.38 cents

.....

NOTES:

1. ORGANISATION AND OPERATIONS

The Company was established as a state-owned enterprise in the People's Republic of China (the "PRC") in 1989. On 29 December 1995, under the relevant provisions of the Company Law of the PRC, the Company was re-organized from a state-owned enterprise to a limited liability company. On 16 August 1996, with the approval of the Economic Restructuring Commission of Jilin Province, the Company was further converted into a joint stock limited company. On 20 April 1999, the Company made a bonus issue from capitalisation of retained profits at the proportion of one bonus share for every two existing shares. The Company's H shares were listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited on 24 May 2001.

The Group is principally engaged in the manufacture and distribution of biochemical medicines in the PRC under the brandnames of Changlong and Shendi.

2. BASIS OF PREPARATION

The unaudited quarterly financial statements of the Group have been prepared in accordance with all applicable Hong Kong Financial Reporting Standards ("HKFRSs"), which collective term includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and interpretations issued by Hong Kong Institute of Certified Public Accountants ("HKICPA"), accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance.

The accounting policies adopted in preparing the unaudited consolidated results for the nine months and three months ended 30 September 2008 are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2007.

The condensed consolidated results for the nine months and three months ended 30 September 2008 are unaudited and have been reviewed by the audit committee of the Company.

3. TURNOVER AND REVENUE

The Group's turnover comprises the invoiced value of merchandise sold net of value added tax and after allowances for returns and discounts.

4. SEGMENTAL INFORMATION

The Group has only one business segment which is in the manufacture and distribution of biochemical medicines in the PRC. For the nine months ended 30 September 2008, turnover of the Group is generated entirely from sales in the PRC and all identifiable assets of the Group are located in PRC. Accordingly, no business or geographical segmental analysis is prepared for the period.

5. TAXATION

	Unaudited For the nine months ended 30 September		Unaudited For the three months ended 30 September	
	2008 RMB'000	2007 RMB'000	2008 RMB'000	2007 RMB'000
PRC income tax	<u>3,830</u>	<u>2,555</u>	<u>1,784</u>	<u>1,087</u>

The PRC income tax is computed according to the relevant laws and regulations in the PRC. The applicable income tax rate was 25% (2007: 33%).

The Group's subsidiary in Hong Kong is subject to Hong Kong profits tax calculated at 16% on the estimated assessable profits. No provision has been made for Hong Kong profits tax as the subsidiary did not earn income subject to Hong Kong profits tax during the period (2007: Nil).

The Group did not have any significant unprovided deferred taxation for the nine months and three months ended 30 September 2008 (2007: Nil).

6. EARNINGS PER SHARE

The calculation of basic earnings per share for the nine months and three months ended 30 September 2008 is based on the unaudited profit attributable to equity holders of approximately RMB11,227,000 and RMB5,188,000 respectively (2007: RMB5,023,000 and RMB2,144,000) and on the weighted average of 560,250,000 and 560,250,000 (2007: 560,250,000 and 560,250,000) shares in issue during the two period ended 30 September 2008 respectively.

There is no diluted earnings per share because there were no dilutive potential shares in existence during the relevant periods.

7. DIVIDENDS

The Board does not recommend the payment of an interim dividend for the nine months ended 30 September 2008 (2007: Nil).

8. RESERVES

	PRC statutory funds						Total
	Share Capital	Share premium	Exchange reserve	Statutory surplus reserve	Staff public welfare fund	Retained profits	
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2007 (Audited)	56,025	51,098	0	23,285	0	75,892	206,300
Net profit for the nine months ended 30 September 2007 (Unaudited)	0	0	0	0	0	5,023	5,023
At 30 September 2007 (Unaudited)	56,025	51,098	0	23,285	0	80,915	211,323
Net profit for the three months ended 31 December 2007 (Unaudited)	0	0	0	0	0	9,499	9,499
Exchange differences arising on translation or overseas operations recognised directly in equity	0	0	221	0	0	0	221
Transfer to statutory surplus reserve	0	0	0	0	0	0	0
Appropriation to statutory surplus reserve	0	0	0	1,670	0	(1,670)	0
Dividend	0	0	0	0	0	0	0
Balance as at 31 December 2007 (Audited)	56,025	51,098	221	24,955	0	88,744	221,043
Net profit for the nine months ended 30 September 2008 (Unaudited)	0	0	0	0	0	11,227	11,227
At 30 September 2008 (Unaudited)	56,025	51,098	221	24,955	0	99,971	232,270

BUSINESS REVIEW AND PROSPECTS

OPERATING RESULTS

For the nine months ended 30 September 2008, the Group recorded a turnover of approximately RMB83.8 million, representing an increase by 28% from RMB65.2 million during the corresponding period in 2007. Profit attributable to shareholders for the nine months ended 30 September 2008 was RMB11.23 million, representing an increase by 123% from RMB5.02 million during the corresponding period in 2007.

This satisfactory result was mainly due to the increase in the sales of the Company's core products, particularly Compound Huonaoshu capsule and Hai Kun Shen Xi capsule. The sales of the Compound Huonaoshu capsule was approximately RMB29.6 million for the nine months ended 30 September 2008. This represented a significant increase from approximately RMB16 million for the same period last year. The sales of the Hai Kun Shen Xi capsule was approximately RMB34.5 million for the nine months ended 30 September 2008. This represented a significant increase from approximately RMB13.4 million for the same period last year. As a result, the profit attributable to the shareholders increased to approximately RMB11,227,000 for the nine months period in 2008, representing a 123% increase from approximately RMB5,023,000 for the same period last year.

The gross profit margin for the period ended 30 September 2008 was approximately 78%, representing a 6% increase as compared to that of 73% for the same period last year. The increment in gross profit margin during the period ended 30 September 2008 was mainly due to the significant increase in the sales of the Compound Huonaoshu capsule and Hai Kun Shen Xi capsule, which have relatively high profit margin of more than 80%.

The selling expense as a percentage of turnover was 46% in 2008. This represented an increase from 44% when compared to the same period last year. The significant increase in selling expenses was due to an increase in the advertising and promotional activities. General and administrative expenses slightly increased from RMB11,422,000 to RMB12,256,000 for the same period in 2008.

BUSINESS REVIEW

Sales performance

The sales of the Compound Huonaoshu capsule, Hai Kun Shen Xi capsule, and Xueshuan Xinmaining capsule were the top three best products sold during the first three quarters of 2008. The selling of Compound Huonaoshu capsule continued to be the Group's core revenue generator. The revenue of the Compound Huonaoshu capsule for the period ended 30 September 2008 was approximately RMB29.6 million, which represents approximately 35% of the Group's total revenue. In addition, the sales of Xueshuan Xinmaining capsule reached approximately RMB4.3 million for the nine months ended 30 September 2008 while that of Hai Kun Shen Xi capsule was over RMB34.5 million. Other product such as Qianlie Guihuang tablet was also considered as important product that contributed significantly to the Group's revenue during the first three quarters of 2008.

Production facilities

During the year 2008, the Board has reviewed all production facilities and has redesigned the assembly lines and reallocated the plant and machinery so as to improve the effectiveness and efficiency of the production lines.

LIQUIDITY AND FINANCIAL RESOURCES

The Group has maintained a sound financial position during this period. For the nine months ended 30 September 2008, the Group's primary source of funds was cash from the operating activities. As at 30 September 2008, the Group had cash and bank balances and consolidated net asset value of approximately RMB32 million and RMB317 million respectively.

For the nine months ended 30 September 2008, the Group mainly generated revenue and incurred costs in Hong Kong dollars and Renminbi. The Directors consider the impact on foreign exchange exposure of the Group is minimal.

GEARING RATIO

As at 30 September 2008, the Group had short-term bank borrowings of RMB6.99 million and a gearing ratio of approximately 2.2 percent. The calculation of the gearing ratio was based on the short-term bank loans and shareholders' equity as at 30 September 2008.

FUTURE PROSPECTS

Looking ahead, the management believed that Hai Kun Shen Xi capsule has reached maturity in the market and it is believed that this medicine will take over the Compound Huonaoshu capsule as our best selling product at the end of this year. For the nine months ended 30 September 2008, the sales of Hai Kun Shen Xi capsule has reached approximately RMB34.5 millions while the sales of Compound Huonaoshu capsule was approximately RMB29.6 millions.

The Directors also would like to take this opportunity to express their gratitude to the management and staff for their dedication and contribution to the Group, and to thank our fellow business partners and equity holders for their continuing support. The Directors will endeavor to explore every potential opportunity for business growth, creating a promising future and successful results in the years ahead.

DIRECTORS' INTERESTS IN SHARES

At 30 September 2008, the interests and short positions of the Directors, supervisors and chief executives of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO") as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules were as follows:

Long positions in shares

Director	Type of Interests	Capacity	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered Share Capital
Zhang Hong	Personal	Beneficial owner	101,937,000	26.28	18.19
Zhang Xiao Guang	Personal	Beneficial owner	42,315,000	10.91	7.55
Mr. Wu Guo Wen	Personal	Beneficial owner	900,000	0.232	0.161
Mr. Chen Qi Ming	Personal	Beneficial owner	300,000	0.077	0.054

Save as disclosed above, as at 30 September 2008, none of the Directors, supervisors and chief executives of the Company has any interests and short positions in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the minimum standards of dealing by directors as referred to in Rule 5.46 to 5.67 of the GEM Listing Rules.

DIRECTORS' RIGHTS TO ACQUIRE SHARES

Apart from as disclosed under the headings "Directors' interests in shares" above, at no time during the period were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any director and chief executives or their respective spouses or children under 18 years of age, or were any such rights exercised by them; or was the Company, its holding company, or any of its subsidiaries a party to any arrangement to enable the directors and chief executives to acquire such rights in any other body corporate.

INTERESTS DISCLOSEABLE UNDER THE SFO AND SUBSTANTIAL SHAREHOLDERS

As at 30 September 2008, the following persons (other than the Directors, supervisors and chief executives of the Company) had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

Long positions in shares

Name of shareholder	Capacity/Nature of Interest	Number of Domestic Shares	Percentage of Domestic Shares	Percentage of total registered share capital
Huinan County SAB <i>(Note)</i>	Beneficial owner	81,975,000	21.14	14.63

Note: Apart from the equity interest in the Company, Huinan County SAB does not have any direct or indirect interest in the Company, including representation in the Board of Directors.

Save as disclosed above, as at 30 September 2008, the Directors were not aware of any other person (other than the Directors, supervisors and chief executives of the Company) who had interests and short positions in the shares and underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO.

COMPETING INTEREST

During the period under review, none of the Directors, the management shareholders, the significant shareholders or the substantial shareholders (as defined in the GEM Listing Rules) of the Company had any interest in a business which competes or may compete with the business of the Group.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

During the nine months ended 30 September 2008, the Company has adopted a code of conduct regarding securities transactions by directors on terms no less than the required standard of dealings as set out in rules 5.48 to 5.67 of the GEM Listing Rules. The Company has also made specific enquiry of all Directors and the Company was not aware of any non-compliance with the required standard of dealings and its code of conduct regarding securities transactions by Directors.

BOARD PRACTICES AND PROCEDURES

During the period under review, the Company had not fully complied with the board practices and procedures as set out in Rules 5.34 of the GEM Listing Rules in respect of the Code on Corporate Governance Practices (the "CCGP"). The main deviations from the code provision set out in the CCGP were as follows:

Under the code provision A.2.1, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Zhang Hong assumes the role of both the chairman and the chief executive officer of the Company. The Board is of the view that this has not compromised accountability and independent decision making for the following reasons:

- the Audit Committee composes exclusively of independent non-executive directors;
- the independent directors have free and direct access to the Company's external auditors and independent professional advice when considered necessary.

.....

Mr. Zhang Hong, the chairman, is a substantial shareholder of the Company and has considerable industry experience. He is motivated to contribute to the growth and profitability of the Group. The Board is of the view that it is in the best interests of the Group to have an executive chairman so that the Board can have the benefit of a chairman who is knowledgeable about the business of the Group and is most capable to guide discussions and brief the Board in a timely manner on pertinent issues and developments to facilitate open dialogue between the Board and the management.

Besides, the Company has only two independent non executive directors and audit committee members and thus is temporarily unable to strictly comply with Rules 5.05 and 5.28 of the GEM Listing Rules. Details are set out in the section "Audit Committee" of the announcement.

AUDIT COMMITTEE

The Company set up an audit committee (the "Committee") on 24 May 2001 with written terms of reference in compliance with the requirements as set out in Rules 5.28 and 5.29 of the GEM Listing Rules. The primary duties of the Committee are to review and provide supervision over the financial reporting procedures and internal control system of the Group.

At 18 April 2006, Mr. Wong Kin Fai, Kenny has resigned as an independent non-executive director ("INED") of the Company and ceased to be a member of Audit Committee. The Company required additional time than expected to identify suitable candidates as new INED and Audit Committee's member. At 28 February 2008, Mr. Xue Change Qing and Mr. Yan Li Jin have been appointed as INEDs and member's of Audit Committee, and Mr. Nan Zheng has resigned as an INED and ceased to be a member of Audit Committee of the Company. During the period from 18 April 2006 to 28 February 2008, the Company has only two INEDs and Audit Committee members and a minimum of three members to comprise the Audit Committee.

The committee has reviewed with the management the accounting principles and practices adopted by the Group and discussed internal controls and financial reporting matters, including a review of the unaudited results of the Group for the period ended 30 September 2008.

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES

During the nine months ended 30 September 2008, neither the Company nor its subsidiaries purchased, sold or redeemed any of the Company's listed shares.

By order of the Board
Zhang Hong
Chairman

Jilin, the PRC
14 November 2008

As at the date of this report, the Board comprises Seven executive directors, being Zhang Hong, Zhang Xiao Guang, Liang Xiao Guang, Tian Xin Guo, Chen Qi Ming, Wu Guo Wen, Zhao Bao Gang and three independent non-executive directors, being Xue Change Qing, Yan Li Jin and Shen Yu Xiang.